Mesoblast Limited vs Nerdwallet Inc — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Nerdwallet Inc trades at $9.04 (market cap $603.70M). The key difference: Mesoblast Limited is far larger — about 3.6× Nerdwallet Inc's market cap, and Mesoblast Limited is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals.
| MESO | NRDS | |
|---|---|---|
Market Cap | $2.17B | $603.70M |
Sector | Technology | Financials |
52-Week High | $20.96 | $15.93 |
52-Week Low | $12.88 | $7.58 |
Enterprise Value | $2.17B | $518.00M |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
NerdWallet (NRDS) trades at $9.17, down 0.97% with a bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.29 versus $0.25 expected. Revenue grew to $836.6M in 2025 with improving net margins from -1.9% in 2022 to 5.82%. Valuation metrics appear attractive with P/E of 9.96 and P/S of 0.81. Recent news highlights the company's pivot to higher-margin transactions and launch of financial resilience indices.
The stock presents a compelling value opportunity with 39% upside to the $12.75 consensus target. Strong profitability metrics (93% gross margin, 19.47% ROE) and positive cash flow trends support the bullish case. Key risks include search-driven revenue headwinds and competitive pressures in financial guidance markets. Analyst consensus leans bullish with 4 buy ratings versus 1 hold and 1 sell.
Trailing returns across standard periods
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →